AIDX 20/20 Biolabs, Inc.
Company Analysis
Latest News
20/20 BioLabs second quarter 2026 revenue grew 37% on record cancer test volume
20/20 BioLabs reported second quarter 2026 revenue of $0.73 million, a 36.5% increase year-over-year, driven by record multi-cancer early detection (MCED)...
🟢 20/20 Biolabs is trading 5.96% up in pre-market — no confirmed catalyst identified
20/20 Biolabs is trading at $0.59, up +5.96% in pre-market, with no confirmed company-specific catalyst identified for August 17, 2026. - The latest reported...
🔴 20/20 Biolabs is trading 6.06% down in pre-market with no confirmed catalyst identified
20/20 Biolabs is trading 6.06% down at $0.52 in pre-market, with no confirmed catalyst identified. - The move reverses the August 14, 2026 close of $0.55. -...
🟢 20/20 Biolabs is trading 6.05% up today
20/20 Biolabs is trading 6.05% up at $0.55 amid supportive broader sentiment after softer inflation reduced expectations for a September Federal Reserve rate...
🟢 20/20 Biolabs is trading 10.54% up today after cooler inflation data supported steady Fed policy
20/20 Biolabs is trading 10.54% up at $0.51 after cooler inflation data supported broader risk-on sentiment. - The move extends its August 12, 2026 close of...
🟢 20/20 Biolabs is trading 6.07% up today amid broader risk-on trading after cooler inflation data
20/20 Biolabs is trading 6.07% up now at $0.49, with the move appearing aligned with broader risk-on trading after July PPI showed no monthly growth and July...
🟢 20/20 Biolabs is trading 10.69% up today as in-line July CPI eased hike expectations
20/20 Biolabs is trading 10.69% up at $0.48, with broader risk-on sentiment following in-line July CPI and reduced interest-rate-hike expectations. - The...
🟢 20/20 Biolabs is trading 8% up today with no clear company-specific catalyst
20/20 Biolabs is trading 7.91% up at $0.47, with no clearly reported company-specific announcement on August 12, 2026. - The company’s latest available...
🔴 20/20 Biolabs is trading 5% down today with no clear catalyst identified
20/20 Biolabs is trading 5.02% down now at $0.44 on August 10, 2026, with no clear company-specific announcement, filing, earnings release, or other catalyst...
AIDX Announces Pilot Program with Giant Food and Reports Strong Q2 Commercial Wins
20/20 Biolabs (AIDX) announced a pilot program with Giant Food for its OneTest for Longevity and reported its best-ever quarterly revenue for cancer testing in...
🔴 20/20 Biolabs is trading 5.6% down today in a pullback after recent speculative gains
20/20 Biolabs is trading 5.6% down at $0.43 as the stock pulls back from recent speculative buying in high-risk small caps. • The move follows a sharp rebound...
🟢 20/20 Biolabs is trading 10.3% up today as investors rotate into high-risk small caps
20/20 Biolabs is trading 10.3% up at $0.47 as investors rotate into higher-risk small-cap names amid improving risk appetite. • The move aligns with a broader...
🟢 20/20 Biolabs is trading 5.3% up today as risk-on sentiment lifts small caps
20/20 Biolabs is trading 5.3% up today at $0.45 as investors continue rotating into higher-risk small-cap names amid improving market sentiment. • The stock...
🟢 20/20 Biolabs is trading 10.6% up today as investors rotate into small-caps
20/20 Biolabs is trading 10.6% up at $0.47 as improving market sentiment drives a rotation back into higher-risk small-cap names. • Major U.S. indices have...
🟢 20/20 Biolabs is trading 5.6% up today amid broader risk-on sentiment
20/20 Biolabs is trading at $0.45 (+5.62%) following a stretch of volatile trading and a broader risk-on market tone. • No company-specific announcements,...
🟢 20/20 Biolabs is trading 5.4% up today with no clear catalyst
20/20 Biolabs is trading 5.4% up at $0.44 in pre-market action despite a lack of fresh company-specific news or catalysts. • The move follows a volatile week...
🔴 20/20 Biolabs is trading 5.3% down today amid speculative micro-cap volatility
20/20 Biolabs is trading at $0.43 (5.3% down), extending a weak recent trend in the thinly traded micro-cap stock. • No fresh company-specific headlines,...
🔴 20/20 Biolabs is trading 6.3% down today, extending recent weak momentum
20/20 Biolabs is trading 6.3% down today at $0.46, extending its recent weak momentum after consecutive declines last week. • The move appears to be a...
🟢 20/20 Biolabs is trading 5.1% up today in a minor bounce after recent weakness
20/20 Biolabs is trading 5.1% up at $0.54 in thin pre-market action, staging a modest rebound after closing at $0.51 on July 23, 2026. • The move appears to...
🔴 20/20 Biolabs is trading 5.2% down today amid broader market weakness and no clear company-specific catalyst
20/20 Biolabs is trading at $0.49, down 5.2% in after-hours sessions, extending a recent multi-day decline from its July 22 level of $0.55. • The downward...